CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, nurses, radiation oncologists, general surgeons and other allied healthcare professionals involved in the treatment of non-small cell lung cancer.
  
  LEARNING OBJECTIVES

  • Recognize the frequency with which patients with metastatic non-small cell lung cancer (NSCLC) progress on first-line immune checkpoint inhibitor-based therapy and optimally select and sequence available therapeutic options to maximize quality and quantity of life.
  • Discern the side effects and toxicities associated with available agents commonly used for the treatment of relapsed/refractory metastatic NSCLC, and implement strategies to manage and mitigate them.
  • Appreciate the biologic rationale for combining immune checkpoint inhibitors with agents targeting the VEGF axis in patients with NSCLC progressing on first-line immunotherapeutic based approaches, and assess published research findings with and ongoing studies evaluating this therapeutic strategy.
  • Appreciate the incidence of various potentially targetable cell surface proteins (eg, TROP2, CEACAM5) in patients with progressive, metastatic NSCLC, and recognize published clinical trial data with and ongoing studies of investigational antibody-drug conjugates (ADCs) directed at these emerging targets.
  • Describe the scientific rationale for the use of tumor treating fields (TTFs) as a therapeutic approach for patients with NSCLC, and appraise the available and emerging efficacy and safety data with TTFs in combination with chemotherapy or immunotherapy for patients with recurrent metastatic disease.
  • Recall ongoing trials evaluating the potential role of novel therapeutic approaches for progressive metastatic NSCLC, and counsel appropriate individuals regarding enrollment.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Corey J Langer, MD
  Director of Thoracic Oncology
  Abramson Cancer Center
  Professor of Medicine
  Perelman School of Medicine
  University of Pennsylvania
  Philadelphia, Pennsylvania
  
  Consulting Fees: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Heat Biologics, Merck, Mirati Therapeutics Inc, Novocure Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Data Safety Monitoring Board or Advisory Board (Co-Chair): Amgen Inc, Oncocyte; Medical Writing: Novartis; Research Funding: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Inovio Pharmaceuticals Inc, Lilly, Merck, Oncocyte, Takeda Pharmaceuticals USA Inc, Trizell; Nonrelevant Financial Relationship: US Department of Veterans Affairs.
  
  Ticiana Leal, MD
  Associate Professor
  Department of Hematology and Oncology
  Director, Thoracic Medical Oncology
  Winship Cancer Institute
  Emory University
  Atlanta, Georgia
  
  Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, EMD Serono Inc, Jazz Pharmaceuticals Inc, Merck, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Catalyst Pharmaceuticals Inc, Daiichi Sankyo Inc, Eisai Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Novocure Inc, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Pfizer Inc; Data and Safety Monitoring Board/Committee: OncoC4.
  
  Karen Reckamp, MD, MS
  Director, Division of Medical Oncology
  Associate Director of Clinical Research
  Clinical Professor, Department of Medicine
  Cedars-Sinai Cancer
  Los Angeles, California
  
  Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Daiichi Sankyo Inc, EMD Serono Inc, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Lilly, Mirati Therapeutics Inc; Contracted Research: Blueprint Medicines, Calithera Biosciences, Daiichi Sankyo Inc, Elevation Oncology, Genentech, a member of the Roche Group, Janssen Biotech Inc.
  
  Jacob Sands, MD
  Physician
  Dana-Farber Cancer Institute
  Assistant Professor
  Harvard Medical School
  Boston, Massachusetts
  
  Advisory Committee: Curadev; Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Guardant Health, Jazz Pharmaceuticals Inc, Medtronic Inc, PharmaMar, Sanofi, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Janssen Biotech Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Lilly, and Novocure Inc.
  
  Release date: September 2023
  Expiration date: September 2024